נולוג'יקס 250 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

BELATACEPT 25 MG/ML

Disponible depuis:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

Code ATC:

L04AA28

forme pharmaceutique:

POWDER FOR CONCENTRATE FOR INFUSION

Mode d'administration:

I.V

Fabriqué par:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Groupe thérapeutique:

BELATACEPT

indications thérapeutiques:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Date de l'autorisation:

2012-08-01